Epicrispr has raised a Series C round after sharing promising early data for EPI-321, a potential new way to treat facioscapulohumeral muscular dystrophy.
Amber Salzman, Epicrispr CEO
August 11, 2026 08:54 AM EDT
Epicrispr secures $90M after early data on epigenetic FSHD treatment
Epicrispr Biotechnologies has raised $90 million for its Series C round after sharing promising early data around a potential new way to treat a rare …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The startup has completed enrollment of an early-stage study testing a first-of-its-kind treatment for facioscapulohumeral…
Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321
Epicrispr reports early cut data showing lean muscle gains on its FSHD epigenetic editing therapy EPI-321, using AI
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high…
A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high…
Spot Biosystems emerges from stealth with $40M raised, reporting early human data showing dystrophin restoration in two children…
